Statera Biopharma IncOver The Counter Market:STAB
- LAST PRICE0.0007
- TODAY'S CHANGE (%)0.0001 (16.6667%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0006 / 0.0006
- Day Range
- 52 Week Range
- Volume25,176
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | STAB |
|---|---|---|
| 01:06 ET | 3000 | 0.0006 |
| 03:12 ET | 3088 | 0.0007 |
| 03:27 ET | 16000 | 0.0007 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Statera Biopharma Inc | 50.0K | 0.0x | --- |
Affymax Inc | 26.2K | 0.0x | --- |
Cannabis Global, Inc. | 209.0K | 0.0x | --- |
Genocea Biosciences Inc | 60.0 | 0.0x | --- |
Acura Pharmaceuticals Inc | 660.0K | -0.5x | --- |
Baudax Bio Inc | 462.1K | 0.0x | --- |
Company Information
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.
Contact Information
- Headquarters
- 2537 Research Boulevard, Suite 201FORT COLLINS, CO, United States 80526
- Phone
- 716-849-6810
- Fax
- 716-849-6820
Executives
- Chairman of the Board, President, Chief Executive Officer
- Michael Handley
- Interim Chief Financial Officer, Executive Vice President - Finance, Interim Chief Accounting Officer
- Christopher Zosh
- Chief Technology Officer
- Robert Buckheit
- Vice President - Global Development
- Andrei Gudkov
- Independent Director
- Satish Chandran
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $50.0K |
|---|---|
Revenue (TTM) | $3.7M |
Shares Outstanding | 71.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.72 |
Book Value | $-0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,363.75% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
